News
03-30-2015, 05:50 AM
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that the China Food and Drug Administration (CFDA) has approved the Company's application to conduct a Phase 2 global clinical trial in ovarian clear cell carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076.
More... (http://www.news-medical.net/news/20150330/CASI-receives-CFDA-approval-for-ENMD-2076-Phase-2-clinical-trial-in-ovarian-clear-cell-carcinoma.aspx)
More... (http://www.news-medical.net/news/20150330/CASI-receives-CFDA-approval-for-ENMD-2076-Phase-2-clinical-trial-in-ovarian-clear-cell-carcinoma.aspx)